Check Cap Ltd Net Income per Employee (CHEK), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Check Cap Ltd  (NASDAQ: CHEK)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

Check Cap Ltd Net Income per Employee

CHEK's Quarterly Results, Trends, Rankings, Statistics
Check Cap Ltd's Income per employee fell in the fourth quarter 2025 on a trailing twelve month basis to $ 108,947, below the company average number of $348,882.
The Healthcare sector has seen employees in only one company achieving higher income per employee than the Check Cap Ltd. While Check Cap Ltd's total ranking has deteriorated compared to the previous quarter from to 1033.


What is Income per Employee Ratio?






CHEK Net Income per Employee (Dec 31 2025)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2023)
IV. Quarter
Y / Y Net Income Change -76.43 % - - - -8.06 %
Net Income per Employee (TTM) $ 108,947 462,316 462,316 462,316 462,316
CHEK's Total Ranking # 1033 # # # #
Seq. Net Income Change - - - - -


CHEK Net Income per Employee Company Ranking
Within: No.
Medical Laboratories Industry # 2
Healthcare Sector # 102
Overall Market # 1033

Net Income per Employee Statistics
High Average Low
$ 502,842 $ 348,882 $ 108,947
(Dec 31 2022)   (Dec 31 2025)







Companies with similar Income per Employee for 12 month ending Dec 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Dec 31 2025Number of Employees Dec 31 2025
Johnson and Johnson  190,369.32 $ 26,804.000  Million 140,800 
Novartis Ag  185,566.05 $ 13,967.000  Million 75,267 
Zoetis Inc   184,344.83 $ 2,673.000  Million 14,500 
Grifols Sa  174,291.94 $ 560.000  Million 3,213 
Puma Biotechnology Inc   173,804.47 $ 31.111  Million 179 
Biogen Inc   172,386.67 $ 1,292.900  Million 7,500 
Intuitive Surgical Inc   169,003.00 $ 2,876.600  Million 17,021 
Kiniksa Pharmaceuticals International Plc  161,215.85 $ 59.005  Million 366 
Sab Biotherapeutics Inc   154,345.15 $ 13.274  Million 86 
Collegium Pharmaceutical Inc   148,628.84 $ 62.870  Million 423 
Iradimed Corporation  135,421.69 $ 22.480  Million 166 
Corcept Therapeutics Inc  134,480.82 $ 98.171  Million 730 
Resmed Inc   130,683.82 $ 1,485.875  Million 11,370 
Carlisle Companies Incorporated  125,542.37 $ 740.700  Million 5,900 
Alnylam Pharmaceuticals Inc   125,498.80 $ 313.747  Million 2,500 
Astrazeneca Plc  123,140.79 $ 10,233.000  Million 83,100 
Alkermes Plc   117,884.88 $ 241.664  Million 2,050 
Soleno Therapeutics Inc  114,780.22 $ 20.890  Million 182 
Inspire Medical Systems inc   109,093.77 $ 145.422  Million 1,333 
Check Cap Ltd  108,947.37 $ 4.140  Million 38 
Biomarin Pharmaceutical Inc  108,320.71 $ 348.901  Million 3,221 
Pfizer Inc  104,160.00 $ 7,812.000  Million 75,000 
Bio rad Laboratories Inc   102,000.00 $ 759.900  Million 7,450 
Idexx Laboratories Inc  96,314.91 $ 1,059.464  Million 11,000 
Cryoport inc   95,258.81 $ 70.301  Million 738 
Globus Medical Inc   89,644.67 $ 537.868  Million 6,000 
Lemaitre Vascular Inc   88,143.51 $ 57.734  Million 655 
Veracyte Inc   87,884.77 $ 66.353  Million 755 
Seres Therapeutics Inc   86,303.03 $ 5.696  Million 66 
Waters Corporation  81,345.44 $ 642.629  Million 7,900 


Date modified: 2026-07-07T09:51:03+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.